Analyst Price Targets — TEVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 30, 2026 10:35 am | Glen Santangelo | Barclays | $38.00 | $33.07 | TheFly | Teva price target raised to $38 from $35 at Barclays |
| January 29, 2026 3:18 pm | — | Scotiabank | $40.00 | $32.90 | TheFly | Teva price target raised to $40 from $35 at Scotiabank |
| January 7, 2026 12:22 pm | — | Truist Financial | $36.00 | $32.11 | TheFly | Teva price target raised to $36 from $32 at Truist |
| January 6, 2026 12:37 pm | — | Jefferies | $40.00 | $31.00 | TheFly | Teva price target raised, named a top 2026 idea at Jefferies |
| December 22, 2025 11:44 am | — | Piper Sandler | $40.00 | $30.35 | TheFly | Teva price target raised to $40 from $30 at Piper Sandler |
| December 18, 2025 12:21 pm | — | Goldman Sachs | $35.00 | $30.06 | TheFly | Teva price target raised to $35 from $31 at Goldman Sachs |
| December 8, 2025 9:27 pm | — | Barclays | $35.00 | $28.33 | TheFly | Teva initiated with an Overweight at Barclays |
| December 4, 2025 9:18 pm | — | Scotiabank | $35.00 | $28.41 | TheFly | Teva initiated with an Outperform at Scotiabank |
| November 6, 2025 2:25 pm | Matt Dellatorre | Goldman Sachs | $28.00 | $24.40 | TheFly | Teva price target raised to $28 from $25 at Goldman Sachs |
| December 18, 2024 12:44 pm | Ashwani Verma | UBS | $28.00 | $21.20 | TheFly | Teva price target raised to $28 from $26 at UBS |
Latest News for TEVA
Teva Pharmaceutical Industries has more than doubled in price over the past year. The Israeli drugmaker, formerly known for producing generics, has made a major move into the specialty drugs space.
Teva Pharmaceutical Industries is a large manufacturer of generic drugs. The company is working to expand into more complex generics and to develop its own drugs.
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded…
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.